title: Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.
abstract: Surgical resection of primary gastric lesions after neoadjuvant or palliative chemotherapy is performed for curative or palliative purpose in locally advanced (LA) or initially metastatic (IM) gastric cancer. We investigated which histomorphologic features were associated with patient prognosis. We examined 143 patients (57 LA and 86 IM) who underwent gastrectomy after chemotherapy between 2000 and 2009. The tumor regression grade (TRG)-determined by examining the residual neoplastic cells and background stromal changes-was evaluated. Progression-free (PFS) and overall survival (OS) were evaluated according to pretherapeutic and posttherapeutic clinicopathologic factors using univariate and multivariate analyses. Because both the LA and the IM groups showed similar trends of PFS and OS according to TRG, the 2 groups were analyzed together. Patients with TRG1 (no residual primary tumor) showed a superior PFS and OS than the remaining TRGs. We defined pathologic complete regression (pCR) as TRG1 with negative lymph nodes (LN) and the others as non-pCR. Sixteen patients (11.1%) had pCR with better PFS (P=0.007) and OS (P=0.006). Initial disease status (LA or IM) remained as independent prognostic factors for PFS (P=0.021) but not for OS (P=0.109). The postoperative negative LN status correlated with good outcome and postoperative diffuse-type histology correlated with poor outcome after multivariate analysis. This study showed that pCR, but not partial regression, provides meaningful prognostic information in gastrectomy after chemotherapy. In addition, postoperative LN positivity and diffuse-type histology were independent poor prognostic factors for PFS and OS.
authors.affiliation: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Young Wha
authors.initials: YW
authors.lastname: Koh
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Min-Hee
authors.initials: MH
authors.lastname: Ryu
authors.forename: Baek-Yeol
authors.initials: BY
authors.lastname: Ryoo
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Park
authors.forename: Jeong Hwan
authors.initials: JH
authors.lastname: Yook
authors.forename: Byung Sik
authors.initials: BS
authors.lastname: Kim
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D011184:Postoperative Period; D011379:Prognosis; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate